Open AccessP1530: PERITRANFUSIONAL C1‐INHIBITOR IN PATIENTS WITH SEVERE COMPLEMENT‐MEDIATED AUTOIMMUNE HEMOLYTIC ANEMIA: AN OPEN LABEL PHASE 2 TRIAL.
Author(s) -
Boer E. C. W.,
Jalink M.,
DelvastoNuñes L.,
Meulenbroek E. M.,
Baas I.,
Janssen S. R.,
Dijkman E. E.,
Gelderman K. A.,
Wouters D.,
Engel M. D.,
Haas M.,
Kersten M.J.,
Jongerius I.,
Zeerleder S.,
Vos J. M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000848976.85981.b3
Subject(s) - autoimmune hemolytic anemia , hemolysis , paroxysmal nocturnal hemoglobinuria , medicine , complement system , immunology , hemolytic anemia , c1 inhibitor , eculizumab , lectin pathway , classical complement pathway , autoantibody , anemia , coombs test , antibody , angioedema